                                                                                                                                   I




                                  113TH CONGRESS
                                     1ST SESSION                          H. R. 842
                                  To expand the research activities of the National Institutes of Health with
                                      respect to functional gastrointestinal and motility disorders, and for
                                      other purposes.




                                                IN THE HOUSE OF REPRESENTATIVES
                                                                FEBRUARY 26, 2013
                                   Mr. SENSENBRENNER (for himself and Mr. MORAN) introduced the following
                                       bill; which was referred to the Committee on Energy and Commerce




                                                                            A BILL
                                  To expand the research activities of the National Institutes
                                     of Health with respect to functional gastrointestinal and
                                     motility disorders, and for other purposes.
                                    1              Be it enacted by the Senate and House of Representa-
                                    2 tives of the United States of America in Congress assembled,
                                    3     SECTION 1. SHORT TITLE.
                                    4              This Act may be cited as the ‘‘Functional Gastro-
                                    5 intestinal and Motility Disorders Research Enhancement
                                    6 Act of 2013’’.
                                    7     SEC. 2. FINDINGS.
                                    8              Congress finds the following:




                                                                                             2
                                    1                        (1) Functional gastrointestinal and motility dis-
                                    2              orders (FGIMDs) are chronic conditions associated
                                    3              with increased sensitivity of the GI tract, abnormal
                                    4              motor functioning, and brain-gut dysfunction.
                                    5                        (2) FGIMDs are characterized by symptoms in
                                    6              the GI tract including pain or discomfort, nausea,
                                    7              vomiting, diarrhea, constipation, incontinence, prob-
                                    8              lems in the passage of food or feces, or a combina-
                                    9              tion of these symptoms.
                                  10                         (3) FGIMDs include conditions such as dys-
                                  11               phagia, gastroesophageal reflux disease, dyspepsia,
                                  12               cyclic vomiting syndrome, gastroparesis, irritable
                                  13               bowel syndrome (IBS), Hirschsprung’s disease,
                                  14               chronic intestinal pseudo-obstruction, bowel inconti-
                                  15               nence, and many others, which affect the esophagus,
                                  16               stomach, gallbladder, small and large intestine, and
                                  17               anorectal areas of the body.
                                  18                         (4) The severity of FGIMDs ranges from mildly
                                  19               uncomfortable to debilitating and in some cases life-
                                  20               threatening.
                                  21                         (5) Effective treatments for the multiple symp-
                                  22               toms of FGIMDs are lacking, and while sufferers
                                  23               frequently use a variety of medications and therapies




                                  24               for symptoms, few patients report satisfaction with
                                  25               available treatments.


                                              •HR 842 IH

                                                                                             3
                                    1                        (6) Patients with FGIMDs frequently suffer for
                                    2              years before receiving an accurate diagnosis, expos-
                                    3              ing them to unnecessary and costly tests and proce-
                                    4              dures including surgeries, as well as needless suf-
                                    5              fering and expense.
                                    6                        (7) The economic impact of FGIMDs is high.
                                    7              The annual cost in the United States for IBS alone
                                    8              is estimated to be between $1.7 billion and $10 bil-
                                    9              lion in direct medical costs (excluding prescription
                                  10               and over-the-counter medications) and $20 billion in
                                  11               indirect medical costs.
                                  12                         (8) FGIMDs frequently take a toll on the work-
                                  13               place, as reflected in work absenteeism, lost produc-
                                  14               tivity, and lost opportunities for the individual and
                                  15               society.
                                  16                         (9) Gastrointestinal symptoms consistent with
                                  17               functional gastrointestinal disorders such as IBS
                                  18               and functional dyspepsia have been recognized as a
                                  19               serious and disabling issue for military veterans,
                                  20               particularly those who have been deployed.
                                  21                         (10) FGIMDs affect individuals of all ages in-
                                  22               cluding children, and pediatric FGIMDs can be par-
                                  23               ticularly serious, leading to a lifetime of painful




                                  24               symptoms and medical expenses associated with
                                  25               management of chronic illness or death.


                                              •HR 842 IH

                                                                                             4
                                    1                        (11) The National Institutes of Health’s Na-
                                    2              tional Commission on Digestive Diseases identified
                                    3              comprehensive research goals related to FGIMDs in
                                    4              its April 2009 report to Congress and the American
                                    5              public entitled ‘‘Opportunities and Challenges in Di-
                                    6              gestive Diseases Research: Recommendations of the
                                    7              National Commission on Digestive Diseases’’.
                                    8     SEC. 3. FUNCTIONAL GASTROINTESTINAL AND MOTILITY
                                    9                             DISORDERS RESEARCH ENHANCEMENT.
                                  10               Part B of title IV of the Public Health Service Act
                                  11 (42 U.S.C. 284 et seq.) is amended by adding at the end
                                  12 the following:
                                  13      ‘‘SEC. 409K. FUNCTIONAL GASTROINTESTINAL AND MOTIL-
                                  14                              ITY DISORDERS.
                                  15               ‘‘The Director of NIH may expand, intensify, and co-
                                  16 ordinate the activities of the National Institutes of Health
                                  17 with respect to functional gastrointestinal and motility dis-
                                  18 orders (in this section referred to as ‘FGIMDs’) by—
                                  19                         ‘‘(1) expanding basic and clinical research into
                                  20               FGIMDs                by       implementing                  the         research   rec-
                                  21               ommendations of the National Commission on Di-
                                  22               gestive Diseases relating to FGIMDs;
                                  23                         ‘‘(2) providing support for the establishment of




                                  24               up to five centers of excellence on FGIMDs at lead-
                                  25               ing academic medical centers throughout the country


                                              •HR 842 IH

                                                                                             5
                                    1              to carry out innovative basic, translational, and clin-
                                    2              ical research focused on FGIMDs;
                                    3                        ‘‘(3) exploring collaborative research opportuni-
                                    4              ties among the National Institute of Diabetes and
                                    5              Digestive and Kidney Diseases, the Office of Re-
                                    6              search on Women’s Health, the Office of Rare Dis-
                                    7              ease Research, and other Institutes and Centers of
                                    8              the National Institutes of Health;
                                    9                        ‘‘(4) directing the National Institute of Diabe-
                                  10               tes and Digestive and Kidney Diseases to provide
                                  11               the necessary funding for continued expansion and
                                  12               advancement of the FGIMDs research portfolio
                                  13               through intramural and extramural research;
                                  14                         ‘‘(5) directing the National Institute of Diabe-
                                  15               tes and Digestive and Kidney Diseases and the Eu-
                                  16               nice Kennedy Shriver National Institute of Child
                                  17               Health and Human Development to expand research
                                  18               into FGIMDs that impact children, such as
                                  19               Hirschsprung’s disease and cyclic vomiting syn-
                                  20               drome, and maternal health, such as fecal inconti-
                                  21               nence; and
                                  22                         ‘‘(6) exploring opportunities to partner with the
                                  23               Department of Defense and the Department of Vet-




                                  24               erans Affairs to increase research and improve pa-
                                  25               tient care regarding FGIMDs that commonly impact


                                              •HR 842 IH

                                                                                             6
                                    1              veterans and active duty military personnel, such as
                                    2              IBS and dyspepsia.’’.
                                    3     SEC. 4. PROMOTING PUBLIC AWARENESS OF FUNCTIONAL
                                    4                             GASTROINTESTINAL                          AND         MOTILITY   DIS-
                                    5                             ORDERS.
                                    6              Part B of title III of the Public Health Service Act
                                    7 (42 U.S.C. 243 et seq.) is amended by adding at the end
                                    8 the following:
                                    9     ‘‘SEC. 320B. PUBLIC AWARENESS OF FUNCTIONAL GASTRO-
                                  10                              INTESTINAL AND MOTILITY DISORDERS.
                                  11               ‘‘The Secretary may engage in public awareness and
                                  12 education activities to increase understanding and recogni-
                                  13 tion of functional gastrointestinal and motility disorders
                                  14 (in this section referred to as ‘FGIMDs’). Such activities
                                  15 may include the distribution of print, film, and web-based
                                  16 materials targeting health care providers and the public
                                  17 and prepared and disseminated in conjunction with pa-
                                  18 tient organizations that treat FGIMDs. The information
                                  19 expressed through such activites should emphasize—
                                  20                         ‘‘(1) basic information on FGIMDs, their symp-
                                  21               toms, prevalence, and frequently co-occurring condi-
                                  22               tions; and
                                  23                         ‘‘(2) the importance of early diagnosis, and




                                  24               prompt and accurate treatment of FGIMDs.’’.
                                              •HR 842 IH

                                    1     SEC. 5. SENSE OF CONGRESS ON THE DEVELOPMENT AND   7
                                    2                             OVERSIGHT OF INNOVATIVE TREATMENT OP-
                                    3                             TIONS FOR FUNCTIONAL GASTROINTESTINAL
                                    4                             AND MOTILITY DISORDERS.
                                    5              It is the sense of Congress that, considering the cur-
                                    6 rent lack of effective treatment options for the global
                                    7 symptoms of functional gastrointestinal and motility dis-
                                    8 orders (in this section referred to as ‘‘FGIMDs’’) and the
                                    9 inherent challenges of developing and bringing such treat-
                                  10 ments to market, the Commissioner of Food and Drugs
                                  11 should continue and accelerate important efforts to im-
                                  12 prove the development and oversight of treatment options
                                  13 for FGIMDs by—
                                  14                         (1) enhancing the commitment to emerging ef-
                                  15               forts like the Patient Reported Outcomes Consor-
                                  16               tium to expedite medical device and drug develop-
                                  17               ment, study appropriate balances between risk and
                                  18               patient benefit, and identify proper endpoints for
                                  19               conditions without clear, biological indicators;
                                  20                         (2) enhancing the commitment to broad efforts
                                  21               like the Critical Path Initiative focused on ensuring
                                  22               that scientific breakthroughs are quickly translated
                                  23               into safe and beneficial treatment options; and
                                  24                         (3) continuing collaboration with patient orga-




                                  25               nizations that treat FGIMDs so that the patient
                                              •HR 842 IH

                                                                                             8
                                    1              perspective is considered when determining the need
                                    2              for innovative treatments.
                                              •HR 842 IH                                   Æ
